Altria Group, Inc. MO

Key data

The business

Altria sells cigarettes to American adults, and mostly one cigarette: Marlboro, through Philip Morris USA, holds about 42% of a shrinking US market. That is the engine. Around it sit smokeless brands (Copenhagen and Skoal, plus the on! nicotine pouch that is the one real grower), the NJOY e-vapor line, and a roughly 8% stake in beer giant AB InBev that mostly muddies the reported profit. The moat is simple and durable: a legally protected brand nobody can advertise, sold to loyal buyers who accept price increases year after year. Volume falls every year; management raises the pack price to more than cover it. That bargain, price for volume, is the entire operating question, and the thing the cashier rings up is the same red-and-white pack it was forty years ago.

The numbers

Two things matter in the sequence: the top line stopped falling, and reported profit swings for a reason that is not the business.

Q4 2025 is derived from the annual filing; its low net income, like Q1 2025's, is the AB InBev mark distorting GAAP, not weak operations. Adjusted profit, the number the company runs on, was $1.48 in Q2 2026, up from a year earlier. The GAAP earnings-per-share line below is noisy for the same reason.

Net revenue slid about 2.7% a year from 2021 to 2025 as volume fell and price only partly caught up. The 2026 first half broke that: $11.5B against $11.4B, up 1.6%, the clearest sign in years that pricing is beating the volume drop rather than trailing it. The math from here is plain. Revenue roughly flat, adjusted profit growing mid-single digits on price and a slowly shrinking share count, and a dividend near 6% covered by free cash flow (a 7.2% free-cash yield). That is a high-single-digit total return if the dividend holds and volume does not crack. The market prices the opposite: a melting ice cube, worth 14 times earnings against peers near 27. My read is that the first-half stabilization says the decline is slower and the pricing more durable than a terminal-decline multiple implies. The print that settles it is two or three straight quarters of flat-to-positive net revenue.

Management

The record is a company managing decline for cash, not chasing growth. Buybacks shrank to $1.0B in 2025 from $3.4B in 2024, and long-term debt came down about $1.5B over five quarters to $24.6B, near 1.9 times cash earnings; the dividend gets first claim on the cash and always has. A $78M restructuring charge this year covers closing smokeless-tobacco plants, sensible housekeeping. Insiders sold about $2.4M across three routine sales over the past year and bought nothing, with plan status not disclosed, too small to read either way.

How it fails or surprises you

Volume falls faster than price can chase. US cigarette shipments have been dropping close to 9-10% a year industry-wide, and this run's bundle again does not carry the exact figure. If smokers quit or trade down faster than Altria can raise the pack price, net revenue reverts to decline. Watch Q3 2026 net revenue against the +1.6% first-half mark; a return below zero is the first real crack.

Regulation moves the floor. An FDA menthol ban, a mandated nicotine cut, or unchecked illicit disposable vapes could pull volume down in a step rather than a drift. Watch for any rule finalization and the smoke-free volume disclosure each quarter.

Smoke-free finally pays (right tail). If on! pouches and NJOY reach real profit scale while the FDA actually enforces against illegal vapes, the mix re-accelerates and a 14x cigarette multiple looks wrong. The market pays nothing for this today. The print: smoke-free revenue and on! can shipments turning clearly positive and margin-accretive.

Closing thoughts

This is mostly a priced instrument: a near-6% dividend plus low-single-digit growth, where the edge is small and the buyer on the other side is the seller who believes the decline is terminal. What is not fully priced is optionality, that pricing power proves more durable and smoke-free eventually earns its keep. The near-term left tail looks thinner than the multiple implies, because the first half shows price beating volume and free cash flow covers the payout with room. The real downside is not this year; it is a volume break or a regulatory step that forces a rethink of dividend growth and derates the stock toward 11-12x. The right tail, a re-rate toward peers, is worth 30% or more, and nobody is paying for it.

The bet is still that Americans keep smoking Marlboro even as fewer of them light up each year, that Altria keeps raising the price faster than it loses customers, and that the near-6% dividend check keeps arriving. It breaks when volume falls faster than price can climb. The one pair that tells you first: quarterly net revenue year-over-year, and the dividend's share of free cash flow. If net revenue turns back negative for two straight quarters, the read is wrong.